Under the collaboration, the companies will evaluate the safety and efficacy of antigen-specific Somamer reagents previously identified and screened as potential candidates in combination with Ixaka's anti-CD3 aptamers.

Ixaka's anti-C3 aptamers are the targeting agents of its in vivo chimeric antigen receptor T therapies and have been applied to engineer aptamer-based, bispecific T-cell engagers (BiTEs).

SomaLogic's reagents will be evaluated for their ability to improve the safety and efficacy of antibody-based, bispecific therapeutics.

Ixaka will lead the experiments to identify and evaluate Somamer candidates, and further work will determine functional in vitro properties of bispecific aptamers in human cell cultures and in vivo anticancer efficacy in mouse models.

Financial details of the collaboration were not disclosed.